JNJ
Johnson & Johnson NYSE Listed Jan 2, 1943$228.39
-2.48%
vs $234.20
Mkt Cap $554.9B
52w Low $149.79
79.6% of range
52w High $248.56
50d MA $230.37
200d MA $215.73
P/E (TTM)
20.7x
EV/EBITDA
14.0x
P/B
6.8x
Debt/Equity
0.6x
ROE
25.9%
P/FCF
28.2x
RSI (14)
54.40
ATR (14)
$4.53
Beta
0.33
50d MA
$230.37
200d MA
$215.73
Avg Volume
8.1M
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
One Johnson & Johnson Plaza · New Brunswick, NJ 08933 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14, 2026 | AMC | 2.68 | 2.70 | +0.7% | 240.10 | -0.1% | -0.6% | -1.7% | -0.2% | -1.5% | -2.0% | — |
| Jan 21, 2026 | AMC | 2.46 | 2.46 | +0.0% | 218.01 | +0.3% | +0.2% | +0.8% | +0.6% | +1.3% | +1.5% | — |
| Oct 14, 2025 | AMC | 2.76 | 2.80 | +1.4% | 190.85 | +0.3% | +0.2% | +0.5% | +0.6% | +0.3% | -0.9% | — |
| Jul 16, 2025 | AMC | 2.68 | 2.77 | +3.4% | 164.78 | -1.0% | -1.1% | +0.4% | +0.4% | +2.2% | +0.7% | — |
| Apr 15, 2025 | AMC | 2.58 | 2.77 | +7.4% | 153.62 | +1.1% | +0.2% | +2.3% | -0.3% | +0.5% | -1.6% | — |
| Jan 22, 2025 | AMC | 1.99 | 2.04 | +2.5% | 145.27 | +0.1% | +0.9% | +0.1% | +4.1% | -1.7% | +0.5% | — |
| Oct 15, 2024 | AMC | 2.21 | 2.42 | +9.5% | 164.10 | -0.1% | +0.1% | +0.1% | +0.4% | -1.4% | +0.4% | — |
| Jul 17, 2024 | AMC | 2.71 | 2.82 | +4.1% | 156.58 | -0.6% | -0.7% | -0.5% | -0.3% | -1.2% | +2.6% | — |
| Apr 16, 2024 | AMC | 2.64 | 2.71 | +2.7% | 144.45 | +0.4% | +0.2% | +0.7% | +1.5% | +0.8% | +0.3% | — |
| Jan 23, 2024 | AMC | 2.27 | 2.29 | +0.9% | 159.81 | -0.0% | -0.5% | +0.4% | -0.0% | -0.1% | -0.4% | — |
| Oct 17, 2023 | AMC | 2.52 | 2.66 | +5.6% | 156.09 | -0.4% | -2.2% | -0.3% | +0.4% | -1.1% | -0.1% | — |
| Jul 20, 2023 | AMC | 2.61 | 2.80 | +7.3% | 168.38 | -0.1% | +1.1% | +0.5% | +0.8% | +0.2% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 | Leerink Partners | Upgrade | Market Perform → Outperform | $265 | $224.26 | $225.82 | +0.7% | +2.7% | +0.2% | -1.8% | +1.0% | +0.5% |
| Apr 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $240.10 | $239.94 | -0.1% | -0.6% | -1.7% | -0.2% | -1.5% | -2.0% |
| Apr 15 | Barclays | Maintains | Equal Weight → Equal Weight | — | $240.10 | $239.94 | -0.1% | -0.6% | -1.7% | -0.2% | -1.5% | -2.0% |
| Apr 15 | Stifel | Maintains | Hold → Hold | — | $240.10 | $239.94 | -0.1% | -0.6% | -1.7% | -0.2% | -1.5% | -2.0% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $241.31 | $242.00 | +0.3% | -1.2% | -0.2% | +0.9% | -0.6% | -1.7% |
| Mar 30 | RBC Capital | Maintains | Outperform → Outperform | — | $240.45 | $243.49 | +1.3% | +0.8% | +0.8% | -0.1% | -0.4% | -0.9% |
| Mar 19 | Barclays | Maintains | Equal Weight → Equal Weight | — | $237.28 | $238.34 | +0.4% | +0.1% | -0.9% | +0.0% | -0.1% | +2.0% |
| Mar 17 | HSBC | Maintains | Buy → Buy | — | $243.19 | $243.58 | +0.2% | -2.1% | -0.3% | +0.1% | -0.9% | +0.0% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $243.71 | $242.87 | -0.3% | -0.3% | -0.4% | -0.2% | +0.7% | -2.1% |
| Mar 5 | JP Morgan | Maintains | Neutral → Neutral | — | $245.30 | $242.63 | -1.1% | -2.3% | +0.3% | +0.9% | +0.5% | -0.3% |
| Feb 3 | RBC Capital | Maintains | Outperform → Outperform | — | $230.75 | $231.50 | +0.3% | +1.0% | +0.6% | +1.4% | +0.9% | -0.6% |
| Jan 28 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $224.44 | $226.40 | +0.9% | +1.5% | -0.2% | -0.0% | +1.5% | +1.0% |
| Jan 27 | Freedom Capital Markets | Maintains | Hold → Hold | — | $221.49 | $222.00 | +0.2% | +1.3% | +1.5% | -0.2% | -0.0% | +1.5% |
| Jan 27 | Freedom Broker | Maintains | Hold → Hold | — | $221.49 | $222.00 | +0.2% | +1.3% | +1.5% | -0.2% | -0.0% | +1.5% |
| Jan 23 | Guggenheim | Maintains | Buy → Buy | — | $218.49 | $219.80 | +0.6% | +0.8% | +0.6% | +1.3% | +1.5% | -0.2% |
| Jan 22 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $218.01 | $218.77 | +0.3% | +0.2% | +0.8% | +0.6% | +1.3% | +1.5% |
| Jan 22 | TD Cowen | Maintains | Buy → Buy | — | $218.01 | $218.77 | +0.3% | +0.2% | +0.8% | +0.6% | +1.3% | +1.5% |
| Jan 22 | Citigroup | Maintains | Buy → Buy | — | $218.01 | $218.77 | +0.3% | +0.2% | +0.8% | +0.6% | +1.3% | +1.5% |
| Jan 22 | BofA Securities | Maintains | Neutral → Neutral | — | $218.01 | $218.77 | +0.3% | +0.2% | +0.8% | +0.6% | +1.3% | +1.5% |
| Jan 22 | Wells Fargo | Maintains | Overweight → Overweight | — | $218.01 | $218.77 | +0.3% | +0.2% | +0.8% | +0.6% | +1.3% | +1.5% |
| Jan 22 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $218.01 | $218.77 | +0.3% | +0.2% | +0.8% | +0.6% | +1.3% | +1.5% |
| Jan 22 | Stifel | Maintains | Hold → Hold | — | $218.01 | $218.77 | +0.3% | +0.2% | +0.8% | +0.6% | +1.3% | +1.5% |
| Jan 9 | Bernstein | Maintains | Market Perform → Market Perform | — | $205.75 | $205.91 | +0.1% | -0.7% | +2.6% | +1.9% | +2.3% | +0.5% |
| Dec 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $207.56 | $207.51 | -0.0% | -0.3% | +0.0% | +0.2% | -1.5% | +0.2% |
| Dec 19 | Goldman Sachs | Maintains | Buy → Buy | — | $208.31 | $207.56 | -0.4% | -0.9% | +0.5% | -0.7% | +1.0% | -0.1% |
| Dec 15 | BofA Securities | Maintains | Neutral → Neutral | — | $211.58 | $210.35 | -0.6% | +1.2% | -2.3% | +0.5% | -1.0% | -0.9% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $210.01 | $210.28 | +0.1% | +0.7% | +1.2% | -2.3% | +0.5% | -1.0% |
| Dec 11 | RBC Capital | Maintains | Outperform → Outperform | — | $206.54 | $207.90 | +0.7% | +1.7% | +0.7% | +1.2% | -2.3% | +0.5% |
| Dec 11 | Citigroup | Maintains | Buy → Buy | — | $206.54 | $207.90 | +0.7% | +1.7% | +0.7% | +1.2% | -2.3% | +0.5% |
| Dec 5 | Guggenheim | Maintains | Buy → Buy | — | $202.48 | $202.98 | +0.2% | -0.3% | -0.2% | -0.8% | +3.3% | +1.7% |
| Dec 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $205.34 | $205.24 | -0.0% | +0.0% | -0.0% | -1.4% | -0.3% | -0.2% |
| Oct 22 | Freedom Capital Markets | Downgrade | Buy → Hold | — | $191.88 | $192.00 | +0.1% | +0.6% | -0.2% | -1.1% | -0.1% | -1.8% |
| Oct 22 | Freedom Broker | Downgrade | Buy → Hold | — | $191.88 | $192.00 | +0.1% | +0.6% | -0.2% | -1.1% | -0.1% | -1.8% |
| Oct 15 | BofA Securities | Maintains | Neutral → Neutral | — | $190.85 | $191.48 | +0.3% | +0.2% | +0.5% | +0.6% | +0.3% | -0.9% |
| Oct 15 | Citigroup | Maintains | Buy → Buy | — | $190.85 | $191.48 | +0.3% | +0.2% | +0.5% | +0.6% | +0.3% | -0.9% |
| Oct 15 | Stifel | Maintains | Hold → Hold | — | $190.85 | $191.48 | +0.3% | +0.2% | +0.5% | +0.6% | +0.3% | -0.9% |
| Oct 15 | Raymond James | Maintains | Outperform → Outperform | — | $190.85 | $191.48 | +0.3% | +0.2% | +0.5% | +0.6% | +0.3% | -0.9% |
| Oct 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $190.85 | $191.48 | +0.3% | +0.2% | +0.5% | +0.6% | +0.3% | -0.9% |
| Oct 14 | UBS | Maintains | Buy → Buy | — | $190.90 | $192.92 | +1.1% | -0.0% | +0.2% | +0.5% | +0.6% | +0.3% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $191.08 | $192.01 | +0.5% | -0.2% | +0.1% | -0.0% | +0.2% | +0.5% |
| Oct 9 | Goldman Sachs | Maintains | Buy → Buy | — | $189.69 | $190.00 | +0.2% | +0.7% | -0.2% | +0.1% | -0.0% | +0.2% |
| Oct 7 | Citigroup | Maintains | Buy → Buy | — | $188.16 | $183.77 | -2.3% | +0.4% | +0.4% | +0.7% | -0.2% | +0.1% |
| Oct 6 | Bernstein | Maintains | Market Perform → Market Perform | — | $188.64 | $188.00 | -0.3% | -0.3% | +0.4% | +0.4% | +0.7% | -0.2% |
| Oct 3 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $185.98 | $187.06 | +0.6% | +1.4% | -0.3% | +0.4% | +0.4% | +0.7% |
| Oct 3 | BofA Securities | Maintains | Neutral → Neutral | — | $185.98 | $187.06 | +0.6% | +1.4% | -0.3% | +0.4% | +0.4% | +0.7% |
| Sep 23 | Guggenheim | Upgrade | Neutral → Buy | — | $174.21 | $174.89 | +0.4% | +1.4% | +0.1% | +0.6% | +1.1% | +1.1% |
| Sep 16 | JP Morgan | Maintains | Neutral → Neutral | — | $177.40 | $177.57 | +0.1% | -0.5% | +0.4% | -1.7% | +1.2% | -1.1% |
| Aug 21 | Citigroup | Maintains | Buy → Buy | — | $178.84 | $178.55 | -0.2% | +0.1% | +0.2% | -0.5% | -1.1% | +0.2% |
| Jul 17 | RBC Capital | Maintains | Outperform → Outperform | — | $164.78 | $163.18 | -1.0% | -1.1% | +0.4% | +0.4% | +2.2% | +0.7% |
| Jul 17 | BofA Securities | Maintains | Neutral → Neutral | — | $164.78 | $163.18 | -1.0% | -1.1% | +0.4% | +0.4% | +2.2% | +0.7% |
No insider trades available.
8-K
Johnson & Johnson -- 8-K Filing
Johnson & Johnson shareholders rejected a proposal requiring an independent board chair while reelecting their auditor, maintaining current governance structure.
Apr 28
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Johnson & Johnson reported Q1 2026 earnings on April 14, 2026; investors should review the detailed financial results and sales data to assess whether the company met expectations and maintained growth momentum.
Apr 14
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 156,605,370 | $38.3B | New | Mar 2026 |
| 2 | Morgan Stanley | 92,651,178 | $19.2B | Reduced | Dec 2025 |
| 3 | Vanguard Portfolio Management Llc | 63,514,436 | $15.5B | New | Mar 2026 |
| 4 | Jpmorgan Chase & Co | 63,096,344 | $15.3B | Added | Mar 2026 |
| 5 | State Farm Mutual Automobile Insurance Co | 31,590,952 | $7.7B | — | Mar 2026 |
| 6 | Northern Trust Corp | 29,319,669 | $7.2B | — | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 25,516,697 | $6.2B | Reduced | Mar 2026 |
| 8 | Fmr Llc | 24,771,828 | $6.1B | Added | Mar 2026 |
| 9 | Bank Of New York Mellon Corp | 21,821,962 | $5.3B | Reduced | Mar 2026 |
| 10 | Wells Fargo & Company/mn | 16,925,454 | $4.1B | New | Mar 2026 |
| 11 | Invesco Ltd. | 15,046,905 | $3.7B | Added | Mar 2026 |
| 12 | Amundi | 13,406,820 | $3.3B | New | Mar 2026 |
| 13 | Royal Bank Of Canada | 13,387,402 | $3.3B | Reduced | Mar 2026 |
| 14 | Nuveen, Llc | 12,490,455 | $3.1B | Added | Mar 2026 |
| 15 | Capital World Investors | 11,749,361 | $2.9B | Added | Mar 2026 |
| 16 | Franklin Resources Inc | 10,474,706 | $2.6B | Reduced | Mar 2026 |
| 17 | Raymond James Financial Inc | 10,238,839 | $2.5B | Reduced | Mar 2026 |
| 18 | Ubs Group Ag | 10,209,327 | $2.5B | Added | Mar 2026 |
| 19 | Capital Research Global Investors | 8,739,988 | $2.1B | Added | Mar 2026 |
| 20 | Janus Henderson Group Plc | 7,872,478 | $1.9B | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$554.85B
Enterprise Value
$574.19B
P/E (TTM)
20.71x
Forward P/E
19.71x
PEG Ratio
0.21x
P/B
6.80x
P/S
5.89x
P/FCF
28.17x
EV/EBITDA
13.99x
Shares Out
2.43B
Financials (TTM)
Revenue
$94.19B
Net Income
$26.80B
EBITDA
$41.05B
Free Cash Flow
$19.70B
Op Cash Flow
$24.53B
EPS Basic
$11.03
EPS Diluted
$11.03
EPS Forward
$11.59
Gross Margin
72.8%
Op Margin
27.2%
Net Margin
28.5%
Balance Sheet
Total Assets
$199.21B
Total Liab.
$117.67B
Total Equity
$81.54B
Cash
$20.10B
LT Debt
$39.44B
Book Value/Sh
$33.58
Debt/Equity
0.59x
Current Ratio
1.03
Quick Ratio
0.77
Returns & Growth
ROE
25.9%
ROA
10.5%
ROIC
13.7%
Rev Growth YoY
+6.0%
EPS Growth YoY
+88.9%
Price Returns
2W
-2.4%
1M
-2.0%
3M
-9.3%
6M
+8.9%
12M
+45.2%
Technicals
52W High
$248.56
52W Low
$149.79
50d MA
$230.37
200d MA
$215.73
RSI (14)
54.40
ATR (14)
$4.53
Beta
0.33
Avg Volume
8.1M
Dividends
Div Rate
$5.10
Div Yield
2.2%
Frequency
4
Ex-Div Date
May 26, 2026
Analyst Price Targets
Consensus
$249.27
High
$283.00
Low
$208.00
Median
$250.00
Data updated apr 24, 2026 9:57am
· Source: financialmodelingprep.com